Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
for Neuroblastoma
Drug: Irinotecan
2 locations incl. Boston
Sponsor: Steven DuBois, MD
Sex: All·Age: 1 - 30
Code: NCT07027748·Phase 1·Recruiting